Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T13:30:32.683Z.
Calculation as of: 2026-10-06T13:30:32.683Z.
Quote observation: 2026-10-06T13:30:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9a6fb48ec682e3cf9a2a3de0b7f1962f0667ac92b413acd908fc1cfb112ec24a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apollomics, Inc. (APLM) | $51.17M | N/A | N/A | N/A | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | N/A | N/A | N/A | N/A |
| Envoy Medical, Inc. (COCH)vs › | $51.72M | 249.86 | 158.30 | 158.03 | 959.94 |
| INmune Bio, Inc. (INMB)vs › | $51.84M | N/A | 1293.91 | 1758.59 | 3330.34 |
| Clene Inc. (CLNN)vs › | $49.84M | 252.97 | 342.08 | 169.55 | 218.69 |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $52.71M | N/A | N/A | N/A | N/A |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $52.80M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $49.40M | 0.27 | 0.38 | 0.71 | 0.59 |
| ImageneBio Inc (IMA)vs › | $53.01M | N/A | 51.20 | 31.27 | 27.74 |
| Celularity Inc. (CELU)vs › | $49.21M | 2.59 | 0.93 | 1.92 | 8.84 |
Half-year reporter: no trailing two-half-year basis, because the newest half-year ended more than 270 days before this quote.
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
